Effect of NOACs on Stroke Severity Compared to Warfarin: A Meta-analysis of Randomized Controlled Trials.
In addition to lowering stroke risk, warfarin use is also associated with reduced stroke severity in patients with atrial fibrillation and acute ischaemic stroke. We sought to determine whether the effect of non-vitamin K oral anticoagulants (NOACs), compared to warfarin, differed by stroke severity. We identified phase III randomised controlled trials with participants who were randomised to receive NOACs or warfarin for stroke prevention in the setting of non-valvular atrial fibrillation. We classified stroke into two categories, fatal or disabling stroke and non-disabling stroke and completed meta-analyses for both outcomes and for comparative case-fatality of stroke among trials. Five randomised controlled trials met our inclusion criteria. In clinical trials evaluating NOACs usually prescribed in clinical practice (4 trials), acute stroke was reported in 1403 (1.86%) participants, 787 (1.04%) in the NOAC group [386 (0.51%) fatal or disabling, 401 (0.53%) non-disabling] and 616 (0.82%) in the warfarin group [367 (0.49%) fatal or disabling, 249 (0.33%) non-disabling]. On meta-analysis NOACs were significantly superior to warfarin (Odds Ratio (OR) 0.77; 95% CI [0.66 to 0.89], I2 = 21%) for fatal or disabling stroke and non-disabling stroke (OR 0.85; 95% CI [0.73 to 0.98], I2 = 2%). The case-fatality of stroke was not different between groups, (OR 0.90, 95% CI [0.75, 1.13], I2 = 0%), but the point-estimate favoured NOACs. In Phase III trials of NOACs, for prevention of stroke in atrial fibrillation, NOACs are associated with a lower risk of both fatal/disabling and non-disabling stroke compared to warfarin.